tradingkey.logo

60 Degrees Pharmaceuticals Inc

SXTP
查看詳細走勢圖
4.160USD
+0.310+8.05%
收盤 02/06, 16:00美東報價延遲15分鐘
4.27M總市值
3.70本益比TTM

60 Degrees Pharmaceuticals Inc

4.160
+0.310+8.05%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+8.05%

5天

+0.24%

1月

+111.00%

6月

+215.15%

今年開始到現在

+104.60%

1年

+50.15%

查看詳細走勢圖

操作建議

60 Degrees Pharmaceuticals Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名101/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為17.60。中期看,股價處於下降通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

60 Degrees Pharmaceuticals Inc評分

相關信息

行業排名
101 / 159
全市場排名
271 / 4521
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看跌

60 Degrees Pharmaceuticals Inc亮點

亮點風險
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
業績高增長
公司營業收入穩步增長,連續3年增長33.28%
業績增長期
公司處於發展階段,最新年度總收入681.35K美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入681.35K美元
估值高估
公司最新PE估值3.70,處於3年歷史高位
機構減倉
最新機構持股52.23K股,環比減少35.34%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉20.00股

分析師目標

基於 2 分析師
買入
評級
17.600
目標均價
+301.83%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

60 Degrees Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

60 Degrees Pharmaceuticals Inc簡介

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
公司代碼SXTP
公司60 Degrees Pharmaceuticals Inc
CEODow (Geoffrey S)
網址https://60degreespharma.com/
KeyAI